Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.
Read more...
Read More Details
Finally We wish PressBee provided you with enough information of ( Amgen just got one step closer to bringing its monthly weight loss drug to market )
Also on site :
- G42 a Mistral AI sa spájajú so zámerom budovať platformy a infraštruktúry umelej inteligencie novej generácie
- Companies turn to AI to navigate Trump tariff turbulence
- Your new sofa could be the first sign tariff inflation is hitting home